Due to high homology between inhibitory FcγRIIB and activating FcγRIIA, no successful Fc engineering to selectively enhance FcγRIIB binding has been reported. Since FcγRIIA is expressed on platelet, antibody could crosslink platelets by binding to FcγRIIA expressed on platelet, and has a risk of inducing thrombosis. Therefore, generation of novel Fc variant (FcγRIIB Binding Enhanced Antibody) with selective enhancement of FcγRIIB binding is neccessary. Engineered FcγRIIB Binding Enhanced Antibody could increase efficacy by inducing inhibitory signal into immune cell with strong FcγRIIB binding, in addition to neutralization of immune-activating antigen.
All products and services are for Research Use Only. Do Not use in humans.
Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.